Filing Details
- Accession Number:
- 0001209191-18-011662
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-02-20 20:22:07
- Reporting Period:
- 2018-02-15
- Accepted Time:
- 2018-02-20 20:22:07
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1604464 | Atara Biotherapeutics Inc. | ATRA | Biological Products, (No Disgnostic Substances) (2836) | 460920988 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1612096 | E. Isaac Ciechanover | 611 Gateway Boulevard Suite 900 South San Francisco CA 94080 | Chief Executive Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2018-02-15 | 2,500 | $45.58 | 260,378 | No | 4 | S | Indirect | See footnote |
| Common Stock | Disposition | 2018-02-15 | 2,433 | $46.71 | 257,945 | No | 4 | S | Indirect | See footnote |
| Common Stock | Disposition | 2018-02-15 | 4,767 | $47.56 | 253,178 | No | 4 | S | Indirect | See footnote |
| Common Stock | Disposition | 2018-02-15 | 300 | $48.25 | 252,878 | No | 4 | S | Indirect | See footnote |
| Common Stock | Disposition | 2018-02-16 | 3,000 | $45.44 | 249,878 | No | 4 | S | Indirect | See footnote |
| Common Stock | Disposition | 2018-02-16 | 1,600 | $46.55 | 248,278 | No | 4 | S | Indirect | See footnote |
| Common Stock | Disposition | 2018-02-16 | 5,100 | $47.91 | 243,178 | No | 4 | S | Indirect | See footnote |
| Common Stock | Disposition | 2018-02-16 | 300 | $48.43 | 242,878 | No | 4 | S | Indirect | See footnote |
| Common Stock | Acquisiton | 2018-02-15 | 3,938 | $0.00 | 812,613 | No | 4 | M | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Indirect | See footnote |
| No | 4 | S | Indirect | See footnote |
| No | 4 | S | Indirect | See footnote |
| No | 4 | S | Indirect | See footnote |
| No | 4 | S | Indirect | See footnote |
| No | 4 | S | Indirect | See footnote |
| No | 4 | S | Indirect | See footnote |
| No | 4 | S | Indirect | See footnote |
| No | 4 | M | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Units | Disposition | 2018-02-15 | 3,938 | $0.00 | 3,938 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | M | Direct |
Footnotes
- Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017.
- The price in Column 4 is a weighted average sale price. The prices actually received ranged from $45.00 to $46.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee.
- The price in Column 4 is a weighted average sale price. The prices actually received ranged from $46.10 to $47.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- The price in Column 4 is a weighted average sale price. The prices actually received ranged from $47.15 to $48.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- The price in Column 4 is a weighted average sale price. The prices actually received ranged from $46.15 to $47.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- The price in Column 4 is a weighted average sale price. The prices actually received ranged from $47.25 to $48.20. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- The price in Column 4 is a weighted average sale price. The prices actually received ranged from $48.30 to $48.55. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- Shares issued upon settlement of vested restricted stock units ("RSUs").
- Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement.
- Fully vested.
- The earlier of (i) January 10, 2021 or (ii) the recipient's termination date.
Billionaire Hedge Funds
